Results 11 to 20 of about 46,788 (276)
Journal of Veterinary Medical Science, 2021 Chimeric antigen receptor (CAR) CAR-T cell therapy targeting CD20 can be a novel adoptive cell therapy for canine patients with B-cell malignancy. After injection of the CAR-T cells in vivo, monitoring circulating CAR-T cells is essential to prove in vivo persistence of CAR-T cells. In this study, we developed a novel monoclonal antibody against canine
Masaya Igase +4 more
openaire +4 more sources
Construction and evaluation of wild and mutant ofatumumab scFvs against the human CD20 antigen
Preparative Biochemistry & Biotechnology, 2022 Several monoclonal antibodies targeting the CD20 have been produced and Ofatumumab is a case in point. Although whole antibodies target cancer cells effectively, their applications are restricted in some ways. Single-chain fragment variable antibodies, rather than employing the entire structure of antibodies, have proven a practical approach for ...
Reza Maleki +2 more
openaire +2 more sources
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection [PDF]
Blood, 2010 AbstractRituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success, a substantial proportion of B-cell lymphomas are unresponsive or develop resistance, hence more potent anti-CD20 monoclonal antibodies (mAbs) are continuously being sought. Here
Beers, Stephen A. +15 more
openaire +6 more sources
Disease progression after R-CHOP treatment associated with the loss of CD20 antigen expression [PDF]
Revista Brasileira de Hematologia e Hemoterapia, 2010 A case of a follicular lymphoma transformed into a CD20(+) is described which progressed with the loss of CD20 expression after 8 cycles of R-CHOP. This phenomenon is not a rare event and has shown poor prognosis. Our purposes are to describe this event and suggest biopsy in relapsed or progressive disease.
Bellesso, Marcelo +5 more
openaire +6 more sources
B cells are capable of independently eliciting rapid reactivation of encephalitogenic CD4 T cells in a murine model of multiple sclerosis [PDF]
, 2018 Recent success with B cell depletion therapies has revitalized efforts to understand the pathogenic role of B cells in Multiple Sclerosis (MS). Using the adoptive transfer system of experimental autoimmune encephalomyelitis (EAE), a murine model of MS ...
Archambault, Angela S +5 more
core +3 more sources
Monoclonal Antibodies: from Development to Clinical Application
Клиническая онкогематология, 2016 The development of monoclonal antibodies (MABs) resulted in revolutionary achievements in diagnosing and treating of oncohematological disorders. The review dwells on the history of the development and improved technologies for production of monoclonal ...
YuI Budchanov
doaj +1 more source
Adaptive immunity in cancer immunology and therapeutics. [PDF]
, 2014 Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
Lockley, M, Spurrell, EL
core +2 more sources
Nanobody based dual specific CARs [PDF]
, 2018 Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich +8 more
core +2 more sources
Iranian biomedical journal, 1996 Iranian Biomedical Journal (IBJ); ISSN 1028 ...
Mohammad Reza Aghasadeghi +9 more
openaire +3 more sources
Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions [PDF]
Journal of Immunotherapy, 2018 Chimeric antigen receptor (CAR)-based adoptive T-cell therapy is a highly promising treatment for lymphoid malignancies, and CD20 is an ideal target antigen. We previously developed a lentiviral construct encoding a third generation CD20-targeted CAR but identified several features that required additional optimization before clinical translation.
Damian J. Green +16 more
openaire +3 more sources